Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Mark Uhlik"'
Autor:
Richard Walsh, Xiaohong Qiu, Mark Uhlik, Paulette Mattson, Michele Gargano, Nadine Ottoson, Anissa S.H. Chan, Nandita Bose, Ben J. Harrison, Jeremy R. Graff, Joanna Cox, Michael Chisamore
Publikováno v:
Poster Presentations.
Background Checkpoint inhibitor (CPI) monotherapies, including pembrolizumab (KEYTRUDA®, pembro), avelumab and atezolizumab have demonstrated modest clinical benefit in chemotherapy-relapsed/refractory TNBC patients (pts) with ~5-10% response rate,
Autor:
Anissa Chan, Nandita Bose, Nadine Ottoson, Xiaohong Qiu, Ben Harrison, Richard Walsh, Paulette Mattson, Michele Gargano, Joanna Cox, Michael Chisamore, Mark Uhlik, Jeremy Graff
Publikováno v:
Poster Presentations.
Background Checkpoint inhibitor (CPI) monotherapy has revolutionized the treatment of melanoma, yet most patients are primary nonresponders or develop secondary resistance. Lack of antigen-specific T cell priming and/or immunosuppressive mechanisms l
Autor:
Nandita Bose, Anissa S.H. Chan, Nadine Ottoson, Adria Jonas, Keith Gordon, Mark Uhlik, Xiaohong Qui, Jeremy R. Graff
Publikováno v:
Cancer Immunology Research. 8:A01-A01
Imprime PGG (Imprime), an intravenously administered, soluble, yeast β-1,3/1,6 glucan, is currently in clinical development with tumor-targeting, antiangiogenic and checkpoint inhibitor antibodies. The fundamental mechanistic rationale for these dif